Form 8-K - Current report:
SEC Accession No. 0000950170-23-019682
Filing Date
2023-05-09
Accepted
2023-05-09 16:13:38
Documents
14
Period of Report
2023-05-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K dsgn-20230509.htm   iXBRL 8-K 60967
2 EX-99.1 dsgn-ex99_1.htm EX-99 165398
3 GRAPHIC img267412975_0.jpg GRAPHIC 11344
  Complete submission text file 0000950170-23-019682.txt   372838

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT dsgn-20230509_pre.xml EX-101.PRE 10677
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT dsgn-20230509.xsd EX-101.SCH 2469
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT dsgn-20230509_lab.xml EX-101.LAB 14572
8 EXTRACTED XBRL INSTANCE DOCUMENT dsgn-20230509_htm.xml XML 5111
Mailing Address 6005 HIDDEN VALLEY ROAD SUITE 110 CARLSBAD CA 92011
Business Address 6005 HIDDEN VALLEY ROAD SUITE 110 CARLSBAD CA 92011 858-293-4900
Design Therapeutics, Inc. (Filer) CIK: 0001807120 (see all company filings)

EIN.: 823929248 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40288 | Film No.: 23902160
SIC: 2834 Pharmaceutical Preparations